KWCN-41 is a selective and efficient inhibitor of RIPK1 kinase with an IC 50 value of 88 nM. KWCN-41 specifically inhibits cell necrosis but does not inhibit apoptosis . KWCN-41 also has anti-inflammatory effects In Vitro KWCN-41 (10, 50, 250 nM; 1 h) inhibits L929 cell necroptosis in a dosedependent manner and increases the number of cells in the viable cell zone. KWCN-41 (10, 50, 250 nM; 0.5, 1.5, 2.5 h) inhibits the phosphorylation of RIPK1/3 and MLKL in L929 cells. KWCN-41 (0-10 μM) inhibits TZ-induced necroptosis of L929 cells in a dose-dependent manner and similarly protects cells from TSZ (TNF-α, Smac mimetic, and z-VAD-FMK)-induced necroptosis of HT-29 and U937 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: L929 cells Concentration: 10, 50, 250 nM Incubation Time: 1 h Result: Inhibited L929 cell necroptosis in a Dosedependent manner and increased the number of cells in the viable cell zone. In Vivo KWCN-41 (10, 25, 40 mg/kg; i.p.; 72 h) dose-dependently inhibits TNF-α-induced death and improves survival in mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Inflammatory mouse model Dosage: 10, 25, 40 mg/kg Administration: i.p.; dissolved in saline containing 10% DMSO and 20% Tween80; 72 h Result: At 25, 40 mg/kg completely inhibited TNF-α induced death in mice, achieving 100% survival compared to 75% survival at 10 mg/kg. Form:Solid IC50& Target:RIPK1 88 nM (IC 50 )